Cindy Neunert, MD

Hematology

Academic Title(s)

  • Assistant Professor of Pediatrics at CUMC

Education & Training

Medical School

Eastern Virginia Medical School

Internship

Eastern Virginia Medical Center

Residency

Eastern Virginia Medical Center

Fellowship

University of Texas Southwestern Medical Center

Conditions

Research & Grants

Go to Publications

Faculty Statement

I am a pediatric hematologist with both clinical and research responsibilities. On the clinical side, I have developed expertise in the management of patients with benign hematologic conditions. I help provide care of children with these diseases at New York Presbyterian Morgan Stanley Children’s Hospital and oversee efforts at this center to coordinate care for children with thrombosis.

I have a Master’s Degree in clinical research and my research activities focus on immune thrombocytopenia pupura (ITP), hemostasis and thrombosis, and sickle cell anemia (SCA). My specific interest is in patient-related outcomes. Patient-related outcomes research helps to understand the impact of the disease and management on patients. It can aid in determining the best treatment approach, especially in the absence of strong evidence from randomized clinical trials. Proper patient-related outcomes can also be used as endpoints in clinical trials; ensuring that treatment will be accepted by patients and lead to clinical relevant results. My efforts in this area have involved assessment of bleeding severity in ITP and understanding health-related quality of life in ITP and SCA. 

Aligned with a research focus on patient-related outcomes my clinical interests extend to novel mechanisms for the delivery of care. This includes development of telemedicine capabilities, use of community health care workers, and innovative mechanisms for patient education. I am currently working to build a comprehensive thrombosis program aimed at determining clinical and individual risk factors for thrombosis in children, addressing safety, education and adherence concerns with long-term anticoagulation, and establishing the ideal length of treatment.

I have a role in both national and international efforts to advance the care of children with these disorders. This involves my leadership role as Chair of the Pediatric ITP Consortium of North America. This consortium is currently conducting investigations to determine the best management for children with ITP who are refractory to initial treatment. I am also involved with the Intercontinental Cooperative ITP Study Group, which is an international study group advancing knowledge regarding the natural history of ITP in children and adults. I was an author on the 2011 American Society of Hematology (ASH) ITP guidelines and am the current Chair of the ASH ITP guidelines panel.

+ Read More